Kiniksa (KNSA) shifts from survival to growth as Arcalyst nears blockbuster sales and pipeline KPL-387 readouts loom—get the ...
Before Jackson took office at ARPA-H, the agency’s chief data officer departed after disagreeing with the administration’s ...
Everyday Health on MSN
How to plan for successful home SCIg self-administration for primary immunodeficiency
Learn how to self-administer SCIg at home for primary immunodeficiency. Tips on preparation, reducing pain, managing ...
Scotland has approved its first CLDN18.2-targeted therapy for advanced gastric and GEJ cancer, expanding options for patients ...
Phase 2 clinical trial will evaluate the safety, translational biology, and exploratory clinical efficacy of VYD2311 in people with Long COVID or ...
Parade on MSN
LeAnn Rimes Shares Step-by-Step Video of Procedure That’s Like an ‘Oil Change for Your Body’
The singer offered fans a glimpse at one of her health secrets.
Explore the complexities of modern oncology, including precision medicine, CAR T-cell therapies, and challenges in breast ...
As deaths rose and treatments failed, morale among healthcare workers was at an all-time low. During that time, Dr. David Thrasher received a call from an Eli Lilly executive announcing emergency use ...
Immunocore is expanding its ImmTAX platform into autoimmune disease, outlining plans to start first‑in‑human trials of ...
The National Institute for Health and Care Excellence has approved a breakthrough combination treatment for lupus nephritis, offering new hope to nearly 12,000 people in England living with the ...
Altuviiio (efanesoctocog alfa) reduced bleeding and was safe for boys and young men with severe hemophilia A, according to a ...
CARVYKTI ® is the first and only BCMA-targeted CAR-T cell therapy approved for the treatment of patients with multiple myeloma who have had at least one prior line of therapy. Globally, CARVYKTI ® is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results